Long‐Term Clinical Outcome and Quality of Life of Children, Adolescents, and Young Adults With Chordoma or Chondrosarcoma Treated With Pencil Beam Scanning Proton Therapy
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31898 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Miriam Vazquez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Zürich, Switzerland. Hauptthemen laut MEDLINE: Quality of Life, Chordoma, Proton Therapy, Chondrosarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background and Aims To assess clinical outcomes and quality of life (QoL) of children, adolescents, and young adults (C‐AYAs) with chordomas (CH) or chondrosarcomas (CS) after pencil beam scanning proton therapy (pbsPT).
Methods
A total of 76 C‐AYAs treated between 1999 and 2023 were included. Median age was 16.6 years (1.5–25.4). A total of 44 (57.9%) were AYAs (15–25 years). Most tumors were CHs ( n = 49; 64.5%) and located in the skull base (68.4%). Median radiation dose was 73.8 Gy (RBE) (54–75.6). A total of 26 (34.2%) patients underwent complete resection. PEDQOL questionnaire was used to assess QoL. Kaplan–Meier and log‐rank tests were used for the analysis.
Results
With a median follow‐up of 88.4 months (range, 1.8–257.6), 9 (11.8%) patients died. Local failure only developed in 9 (11.8%) patients. Two (2.6%) presented with distant failure only and another (1.3%) had both. Seven‐years overall survival (OS), local control (LC), and distant control (DC) were 86.3%, 87.7%, and 95.7%, respectively. Children when compared to AYAs had worse 7‐years DC (90% vs. 100%, p = 0.049). Surgical resection vs. biopsy was associated with better 7‐years LC (87.1% vs. 67.7%, p = 0.031). Recurrent tumors showed worse OS, LC, and DC (94.5% vs. 44.6%, p < 0.001; 93.2% vs. 36.6%, p < 0.001; 98.3% vs. 77.6%, p = 0.003). Seven‐years freedom from grade ≥3 late toxicity was 83.1%. Three (3.9%) children with CH developed secondary tumors. QoL did not differ from a healthy cohort 2 years after pbsPT.
Conclusions
Excellent clinical outcomes with acceptable long‐term toxicity and QoL were observed for C‐AYAs with CH/CS after pbsPT. Recurrent tumors, young age, and lack of surgical resection were associated with worse prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Zürich, Switzerland.
- Department of Paediatric Haematology and Oncology, University Hospital Bonn, Bonn, Germany.
ORCID-Profile: Miriam Vazquez, Damien C Weber
Zitieren
APA
Vazquez, M., Cherchik, A., de Angelis, C., Pica, A., Calaminus, G., & Weber, D. C. (2025). Long‐Term Clinical Outcome and Quality of Life of Children, Adolescents, and Young Adults With Chordoma or Chondrosarcoma Treated With Pencil Beam Scanning Proton Therapy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31898
Vancouver
Vazquez M, Cherchik A, de Angelis C, Pica A, Calaminus G, Weber DC. Long‐Term Clinical Outcome and Quality of Life of Children, Adolescents, and Young Adults With Chordoma or Chondrosarcoma Treated With Pencil Beam Scanning Proton Therapy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31898
BibTeX
@article{Vazquez2025,
author = {Vazquez, Miriam and Cherchik, Alexey and de Angelis, Claudio and Pica, Alessia and Calaminus, Gabriele and Weber, Damien C},
title = {Long‐Term Clinical Outcome and Quality of Life of Children, Adolescents, and Young Adults With Chordoma or Chondrosarcoma Treated With Pencil Beam Scanning Proton Therapy},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31898}
}
EUVIMED